-+ 0.00%
-+ 0.00%
-+ 0.00%

EQL Pharma Sees Supply Disruptions Easing, Warns Challenges Persist

PUBT·11/05/2026 06:06:18
EQL Pharma Sees Supply Disruptions Easing, Warns Challenges Persist
  • EQL Pharma’s supply disruptions eased in fiscal 2026/27’s second quarter, but the business has not yet fully recovered.
  • The acute troubleshooting phase is considered over; operational restructuring remains necessary to address complexity created by rapid growth.
  • A balance-sheet review resulted in SEK 15 million in write-downs covering supplier claims and inventory destruction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202611050100BITN____UKPR__SV_20261104-BIT-4972-0) on November 05, 2026, and is solely responsible for the information contained therein.